Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

Congress Details

September 26-29, 2025

Minneapolis, MN, USA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Congress Materials

hfsa

Presentation Type

Poster

Location

Minneapolis, MN, USA

Title

Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life

Helios-B

Presentation Type

Presentation

Location

Minneapolis, MN, USA

Title

Outcomes of the HELIOS-B monotherapy population: A post-hoc analysis censoring data following tafamidis initiation

Helios-B-analysis

Presentation Type

Presentation

Location

Minneapolis, MN, USA

Title

Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B

Login and Sign up

Left Image

RNAiScience Data Hall is for healthcare professionals. By creating an account, you will have access to:

- All RNAi on-demand educational content
- Personalization experience with ability to bookmark content for future reference

First Name *

Last Name *

Enter your Institution Email *

Password *

Country *

Select Speciality *

Select Profession *

* Required Fields

By signing up you agree to Alnylam Terms of Conditions and Privacy Policy.